Corona Remedies IPO Analysis & Latest Update

Subscription Day 3 | GMP Trends | Full Investment Rationale (December 10, 2025)

The Corona Remedies IPO is in its final hours today, and investor interest is clearly strong. With oversubscription across categories and a rising Grey Market Premium (GMP), this IPO has gathered significant attention from retail and high-net-worth investors. As the market gears up for yet another pharma listing, it’s important to understand the issue details, financial fundamentals, growth story, and valuation comfort before making an investment decision. This easy-language article breaks down every aspect of the IPO in simple terms without complicated jargon.

Corona Remedies IPO Issue Details

The Corona Remedies IPO opened on December 8, 2025, and closes today, December 10, 2025. The price band for the issue is ₹1,008 to ₹1,062 per share, and the lot size is 14 shares, making the minimum retail investment around ₹14,868 at the upper band.

The total IPO size stands at ₹655.37 crore, and it is entirely an Offer For Sale (OFS). No fresh capital is being raised, meaning the money from the IPO will go to existing shareholders who are partially exiting. This reflects that the company does not currently require major debt repayment or manufacturing expansion funding from the IPO proceeds.

The company is expected to list on the BSE and NSE on December 15, 2025. Allotment results will be announced tomorrow, December 11, and refunds/credit of shares will follow on December 12.

Subscription Status: Strong Demand Across Categories

As of the end of Day 2, the Corona Remedies IPO has recorded impressive subscription numbers. The overall subscription stands at 9.33 times, showing clear interest from all investor classes.

Category Breakdown

• Non-Institutional Investors (NII): 26.80x
  This category has shown the strongest demand. HNIs generally look for quick listing gains, and the strong GMP seems to be influencing participation.

• Retail Investors: 6.37x
  Healthy participation from retail investors indicates confidence in the brand, valuation, and expected listing pop.

• Qualified Institutional Buyers (QIB): 1.67x
  QIB subscription is modest but expected to surge significantly on the final day, as institutions usually bid heavy on Day 3.

• Employee Quota: 4.03x
  Strong interest from employees suggests internal trust in the company’s future prospects.

Overall, the subscription trend indicates solid demand, especially from investors seeking near-term listing gains.

Grey Market Premium (GMP) and Expected Listing Price

The Grey Market Premium for Corona Remedies has remained strong throughout the IPO period. The current GMP is in the range of ₹265 to ₹290 per share.

This puts the expected listing price at around ₹1,327 to ₹1,352, which means estimated listing gains of 25% to 27%.

While GMP is not an official indicator, it is often considered a reflection of market sentiment. The sustained premium shows that traders expect the IPO to list with healthy gains if broader market conditions remain stable.

Valuation Check: Fairly Priced Compared to Peers

At the upper price band of ₹1,062, Corona Remedies is valued at a P/E of around 43.5x based on FY25 earnings. Compared to other branded-formulation pharma players, the peer group average P/E stands at around 49.7x.

This indicates that Corona Remedies is priced slightly below its peer average, despite delivering stronger growth than many of them. Leading brokerage houses — including Geojit, Nirmal Bang, and BP Equities — have rated the IPO as “Fairly Priced” or “Subscribe for Long Term”.

The valuation appears reasonable, especially considering the company’s consistent revenue growth, high return ratios, and strong competitive positioning.

Company Profile: Who Is Corona Remedies?

Official website visit now

Corona Remedies is an Ahmedabad-based pharmaceuticals company focused primarily on branded formulations. Unlike commodity generic manufacturers, this company sells prescription-led, brand-driven medicines in specialised therapeutic categories.

Key Therapeutic Focus Areas

• Women’s healthcare

• Pain management

• Urology

• Cardio-diabeto

These segments are among the fastest-growing categories in India’s pharmaceutical market, giving the company a natural advantage.

Corona Remedies ranks:

• 6th in India for women’s healthcare, and

• 5th in India for pain management

This strong positioning in high-value therapies sets the company apart.

Manufacturing Facilities and Expansion Plans

Corona Remedies currently operates two manufacturing facilities — one in Gujarat and the other in Himachal Pradesh. In addition to these, the company is setting up a third hormone-specialised manufacturing unit, which is expected to significantly strengthen its women’s health portfolio.

The hormone segment is a fast-growing area, and having an in-house facility can improve margins, reduce outsourcing dependence, and build long-term competitive strength.

Financial Performance: Steady Growth with Strong Profitability

Corona Remedies has delivered consistent growth over the last few years. Here’s a simplified table demonstrating its financial performance:

Corona Remedies: Financial Snapshot

Financial Analysis Explained in Simple Words

Corona Remedies isn’t a turnaround company — it’s already profitable and performing well. Its revenue has increased steadily from ₹884 crore in FY23 to ₹1,196 crore in FY25, growing faster than the overall Indian pharmaceutical market.

The company’s PAT has grown even faster, rising sharply to ₹149.4 crore in FY25, thanks to improved margins and cost efficiencies.

The jump in PAT margin from 9.6% to 12.5% shows that the company is benefitting from operational leverage — higher production volumes and improved product mix are boosting profits.

High return ratios — ROE of nearly 25% and ROCE of over 30% — indicate that the company uses capital effectively and generates strong returns for shareholders.

Overall, the financial track record is strong, consistent, and well-aligned with a long-term growth story.

Why Analysts Are Bullish on Corona Remedies

Brokerage houses have highlighted several strengths that support the company’s long-term potential. Here are the most important reasons:

1. Strong Focus on High-Growth, High-Margin Therapies

Women’s health, urology, and pain management are profitable categories that grow faster than other pharma segments. Corona Remedies has deep strengths in these therapies and strong brand recall.

2. Doctor-Driven Prescription Business

A large share of the company’s revenue comes from specialists and super-specialists. This premium prescription base ensures sticky demand, better pricing power, and higher margins.

3. Fastest-Growing Among Peers

The company is among the fastest-growing players in the top 30 Indian pharma companies, delivering 16.8% revenue CAGR vs the industry average of around 9%.

4. New Hormone Facility Boosting Future Growth

The upcoming hormone plant will elevate the company’s product portfolio and create a new revenue engine over the next few years.

5. Strong Profitability and Balance Sheet

High margins, strong cash flows, lean debt levels, and high ROE make the company financially robust.

Official website  of NSE  CLICK HERE

Risks Investors Should Consider

Every IPO comes with risks, and Corona Remedies has a few areas investors must keep in mind:

• Heavy dependence on top brands – any impact on a few leading brands could hurt revenue.

• Regional concentration, especially in Western India.

• Compliance risks common in the pharma sector.

• No fresh issue means no new capital for expansion; growth must come from internal resources.

Despite these risks, the company’s strong fundamentals offer comfort to long-term investors.

Final Verdict: Should You Apply for Corona Remedies IPO?

With strong subscription numbers, a rising GMP, and a solid financial foundation, the Corona Remedies IPO has shaped up as a promising opportunity.

Short-Term (Listing Gain) View

Given the 25–27% expected listing gain, strong NII participation, and steady market sentiment, the IPO shows good potential for listing-day profits.

Long-Term View

Corona Remedies offers consistent revenue growth, rising profitability, strong return ratios, and leadership in high-growth therapy areas. Long-term investors may find value in holding this stock beyond listing.

Conclusion

The Corona Remedies IPO stands out as a robust pharmaceutical opportunity with clear strengths in branded formulations, strong financials, and attractive valuation relative to peers. With the issue closing today and listing expected on December 15, investors should make their decision based on their appetite for short-term gains and long-term growth potential.